Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Lenacapavir is a long-acting injectable drug that has proven 100 per cent successful in clinical tests and subsequent human ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Lenacapavir is a US Food and Drug Administration (FDA) approved medication indicated for the treatment of HIV type 1 (HIV-1) infection in heavily treatment-experienced adults facing multi-drug ...

Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...